Eurobio Scientific Presents Data on Breast Cancer Treatment Decisions

Eurobio Scientific shared insights in September 2022 regarding breast cancer treatment decisions, presented in conjunction with the European Society for Medical Oncology (ESMO) Annual Congress. The company's EndoPredict gene assay helps clinicians guide therapeutic choices for patients diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer.

Dr. Anastasia Constantinidou presented data at the congress demonstrating how the EndoPredict test can be utilized to inform treatment strategies. Specifically, the test aims to identify patients who are unlikely to benefit from chemotherapy, thereby enabling the avoidance of overtreatment.

This approach is particularly relevant for postmenopausal patients, and the newly presented data extends its potential application to premenopausal women. The objective is to tailor treatment based on individual patient characteristics and improve quality of life by minimizing unnecessary interventions.

Eurobio Scientific, operating in the field of genomic analysis and in vitro diagnostics across Europe, emphasized the significance of research findings in clinical decision-making. The company continues to develop and market diagnostic tools that support more precise and personalized cancer care.